Conceptio
›
Archive
›
ClinicalTrials.gov
ClinicalTrials.gov
public full text
Adjuvant Tislelizumab Plus Lenvatinib for Patients at High-risk of HCC Recurrence After Curative Resection or Ablation
Guangxi Medical University
· 2024
ClinicalTrials.gov · Datasets · License: Public Domain · 2024
Open Source ↗
hepatocellular-carcinoma
immune-checkpoint-inhibitor
recurrence
hepatocellular carcinoma, recurrence, immune checkpoint inhibitor, interventional, phase3
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Related documents
A Study to Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids
#1033719
The Effect of Nicorandil on Rheumatoid Arthritis Patients
#1033725
Imaging Procedure Using ALA in Finding Residual Tumor in Grade IV Malignant Astrocytoma
#1033716
Acupuncture for Heel Pain Syndrome
#1033717
Results of Endoscopic Sinus Surgery in Management of Ophthalmological Complications of Chronic Rhino Sinusitis
#1033721
Record
· ID 803326
Retrieved via
Conceptio
— every document is proof-bundled with source, license, and retrieval metadata.